Voyager Therapeutics, Inc. (VYGR)
1.62
+0.01
(+0.62%)
USD |
NASDAQ |
Nov 20, 09:50
Voyager Therapeutics Cash from Investing (Quarterly) : 29.27M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 29.27M |
| June 30, 2026 | 15.39M |
| March 31, 2026 | 8.101M |
| December 31, 2025 | 47.42M |
| September 30, 2025 | 34.89M |
| June 30, 2025 | 1.933M |
| March 31, 2025 | 41.20M |
| December 31, 2024 | -27.20M |
| September 30, 2024 | 64.35M |
| June 30, 2024 | -35.94M |
| March 31, 2024 | -96.06M |
| December 31, 2023 | 26.83M |
| September 30, 2023 | -158.30M |
| June 30, 2023 | -24.66M |
| March 31, 2023 | 14.49M |
| December 31, 2022 | 14.07M |
| September 30, 2022 | 34.72M |
| June 30, 2022 | -36.13M |
| March 31, 2022 | -20.00M |
| December 31, 2021 | -5.464M |
| September 30, 2021 | 14.34M |
| June 30, 2021 | 22.40M |
| March 31, 2021 | 34.62M |
| December 31, 2020 | -21.52M |
| Date | Value |
|---|---|
| September 30, 2020 | 27.36M |
| June 30, 2020 | -1.838M |
| March 31, 2020 | 108.99M |
| December 31, 2019 | 26.46M |
| September 30, 2019 | 22.61M |
| June 30, 2019 | -2.888M |
| March 31, 2019 | -136.66M |
| December 31, 2018 | 28.63M |
| September 30, 2018 | -1.193M |
| June 30, 2018 | -59.37M |
| March 31, 2018 | 58.40M |
| December 31, 2017 | -60.10M |
| September 30, 2017 | -2.768M |
| June 30, 2017 | 38.53M |
| March 31, 2017 | 20.66M |
| December 31, 2016 | -14.14M |
| September 30, 2016 | 6.611M |
| June 30, 2016 | 42.76M |
| March 31, 2016 | 12.07M |
| December 31, 2015 | -99.58M |
| September 30, 2015 | -10.51M |
| June 30, 2015 | -84.53M |
| March 31, 2015 | -0.15M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Lineage Cell Therapeutics, Inc. | -5.147M |
| Armata Pharmaceuticals, Inc. | -0.091M |
| Black Diamond Therapeutics, Inc. | 4.218M |
| Invivyd, Inc. | -0.585M |
| Elicio Therapeutics, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -19.67M |
| Cash from Financing (Quarterly) | 3.033M |
| Free Cash Flow | -109.83M |
| Free Cash Flow Per Share (Quarterly) | -0.3181 |
| Free Cash Flow to Equity (Quarterly) | -17.61M |
| Free Cash Flow to Firm (Quarterly) | -19.67M |
| Free Cash Flow Yield | -109.0% |